|The following article features coverage from the American Society of Clinical Oncology 2019 meeting. Click here to read more of Cancer Therapy Advisor‘s conference coverage.|
Elderly, frail patients with advanced gastroesophageal cancer who received lower doses of chemotherapy did not have worse survival outcomes compared with those who received full doses of chemotherapy, according to data from the prospective, phase 3, randomized, multicenter, noninferiority GO2 trial. The trial results, which will be presented at the upcoming 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, suggest that a lower dose of chemotherapy can be offered to these patients without compromising efficacy.1
The trial included 514 patients who were considered to be unfit for a full dose of a 3-drug chemotherapy regimen, but suitable for a reduced intensity chemotherapy regimen. Patients were randomized to receive 1 of 3 doses of oxaliplatin plus capecitabine: full dose, intermediate dose (80% of full dose), or low dose (60% of full dose).
The trial confirmed that, compared with the full dose, the 2 lower doses of chemotherapy were noninferior in terms of progression-free survival and overall survival among elderly, frail patients with advanced gastroesophageal cancer. In addition, patients who received the lowest dose (60% of full dose) had the best overall treatment utility score compared with patients who received the intermediate and full doses. Overall treatment utility was a composite measure that factored in cancer control, side effects, quality of life, and the patient’s view of their outcomes.
“Low-dose treatment may be offered to patients who are suitable for chemotherapy but considered either too frail or too elderly for a full-dose standard regimen,” concluded the study presenter Peter S. Hall, PhD, a medical oncologist at the University of Edinburgh, United Kingdom, during a preconference press briefing.
Read more of Cancer Therapy Advisor‘s coverage of ASCO’s annual meeting by visiting the conference page.
- Hall PS, Swinson D, Waters JS, et al. Optimizing chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): The GO2 phase III trial. Presented at: 2019 American Society of Clinical Oncology Annual Meeting; Chicago, IL; May 31-June 4, 2019. Abstract 4006.